ATE223404T1 - Monoargininylsalz der (e)-3-(1-n-butyl-5-((2-(2- carboxyphenyl)methoxy-4-chlorphenyl)-1h-pyrazol 4-yl)-2-((5-methoxy-2,3-dihydrobenzofuran-6- yl)methyl)-prop-2-en carbonsäure - Google Patents

Monoargininylsalz der (e)-3-(1-n-butyl-5-((2-(2- carboxyphenyl)methoxy-4-chlorphenyl)-1h-pyrazol 4-yl)-2-((5-methoxy-2,3-dihydrobenzofuran-6- yl)methyl)-prop-2-en carbonsäure

Info

Publication number
ATE223404T1
ATE223404T1 AT98961951T AT98961951T ATE223404T1 AT E223404 T1 ATE223404 T1 AT E223404T1 AT 98961951 T AT98961951 T AT 98961951T AT 98961951 T AT98961951 T AT 98961951T AT E223404 T1 ATE223404 T1 AT E223404T1
Authority
AT
Austria
Prior art keywords
methoxy
chlorphenyl
dihydrobenzofuran
carboxyphenyl
pyrazole
Prior art date
Application number
AT98961951T
Other languages
English (en)
Inventor
Joseph Robert Flisak
Albert Stephen Kearney
Nagesh Palepu
Cherng-Yih Perng
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE223404T1 publication Critical patent/ATE223404T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98961951T 1997-12-08 1998-12-07 Monoargininylsalz der (e)-3-(1-n-butyl-5-((2-(2- carboxyphenyl)methoxy-4-chlorphenyl)-1h-pyrazol 4-yl)-2-((5-methoxy-2,3-dihydrobenzofuran-6- yl)methyl)-prop-2-en carbonsäure ATE223404T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6773297P 1997-12-08 1997-12-08
PCT/US1998/025903 WO1999029685A1 (en) 1997-12-08 1998-12-07 (e)-3-[1-n-butyl- 5-[2-(2-carboxyphenyl)methoxy- 4-chlorophenyl]-1h- pyrazol-4-yl]-2-[(5- methoxy-2,3- dihydrobenzofuran-6-yl)methyl]- prop-2-enoic acid monoargininyl salt

Publications (1)

Publication Number Publication Date
ATE223404T1 true ATE223404T1 (de) 2002-09-15

Family

ID=22078027

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98961951T ATE223404T1 (de) 1997-12-08 1998-12-07 Monoargininylsalz der (e)-3-(1-n-butyl-5-((2-(2- carboxyphenyl)methoxy-4-chlorphenyl)-1h-pyrazol 4-yl)-2-((5-methoxy-2,3-dihydrobenzofuran-6- yl)methyl)-prop-2-en carbonsäure

Country Status (24)

Country Link
US (1) US6300359B1 (de)
EP (1) EP1037888B1 (de)
JP (1) JP2001525405A (de)
KR (1) KR20010040292A (de)
CN (1) CN1281447A (de)
AR (1) AR017426A1 (de)
AT (1) ATE223404T1 (de)
AU (1) AU747108B2 (de)
BR (1) BR9813409A (de)
CA (1) CA2312965A1 (de)
CO (1) CO5021171A1 (de)
DE (1) DE69807745T2 (de)
DK (1) DK1037888T3 (de)
ES (1) ES2182383T3 (de)
HU (1) HUP0100423A3 (de)
IL (1) IL136592A (de)
NO (1) NO20002904L (de)
NZ (1) NZ504898A (de)
PL (1) PL341601A1 (de)
PT (1) PT1037888E (de)
TR (1) TR200001633T2 (de)
TW (1) TW505643B (de)
WO (1) WO1999029685A1 (de)
ZA (1) ZA9811154B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2007067779A2 (en) * 2005-12-08 2007-06-14 Tsrl, Inc. Methods and compositions for drug delivery enhancement
CN102014878B (zh) 2007-11-05 2013-10-23 夏威夷大学 用于口服给药极性药剂的提高生物利用度的制剂
US8805519B2 (en) 2010-09-30 2014-08-12 Nevro Corporation Systems and methods for detecting intrathecal penetration
AU2018231031B2 (en) 2017-03-09 2023-11-02 Nevro Corp. Paddle leads and delivery tools, and associated systems and methods
US11420045B2 (en) 2018-03-29 2022-08-23 Nevro Corp. Leads having sidewall openings, and associated systems and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
BR9609914A (pt) * 1995-08-02 1999-07-06 Smithkline Beecham Corp Antagonista do receptor de endotelina

Also Published As

Publication number Publication date
AU747108B2 (en) 2002-05-09
AU1713899A (en) 1999-06-28
PT1037888E (pt) 2002-12-31
IL136592A0 (en) 2001-06-14
CO5021171A1 (es) 2001-03-27
CN1281447A (zh) 2001-01-24
KR20010040292A (ko) 2001-05-15
NO20002904D0 (no) 2000-06-07
HK1032229A1 (en) 2001-07-13
PL341601A1 (en) 2001-04-23
HUP0100423A3 (en) 2002-08-28
JP2001525405A (ja) 2001-12-11
NO20002904L (no) 2000-06-07
DE69807745D1 (de) 2002-10-10
WO1999029685A1 (en) 1999-06-17
NZ504898A (en) 2002-11-26
EP1037888A4 (de) 2001-08-22
ES2182383T3 (es) 2003-03-01
DE69807745T2 (de) 2003-05-15
CA2312965A1 (en) 1999-06-17
US6300359B1 (en) 2001-10-09
TW505643B (en) 2002-10-11
DK1037888T3 (da) 2003-01-06
HUP0100423A2 (hu) 2002-05-29
EP1037888B1 (de) 2002-09-04
BR9813409A (pt) 2000-10-10
TR200001633T2 (tr) 2001-07-23
IL136592A (en) 2003-03-12
ZA9811154B (en) 1999-06-08
EP1037888A1 (de) 2000-09-27
AR017426A1 (es) 2001-09-05

Similar Documents

Publication Publication Date Title
EE200100268A (et) Asendatud pürasoolid p38 kinaasi inhibiitoritena
ATE391126T1 (de) Kristalline form des (r)-2-(((3-methyl-4-(2,2,2- trifluorethoxy)-2-pyridinyl)methyl)sulfinyl)-1h benzimidazols
DE60233043D1 (de) 2-iminoimidazolderivate
DE60126828D1 (de) "pyrazolverbindungen, die sich als proteinkinaseinhibitoren eignen"
MA26837A1 (fr) Heterocycles azotes bicycliques heteroalky-lamino substitues en tant qu'inhibiteurs de kinase de proteine p38.
ID16867A (id) Garam-garam dihidrat mesilat 5-(2-(4-1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-kloro-1,3-dihidro-2h-indol-2-on
ATE223404T1 (de) Monoargininylsalz der (e)-3-(1-n-butyl-5-((2-(2- carboxyphenyl)methoxy-4-chlorphenyl)-1h-pyrazol 4-yl)-2-((5-methoxy-2,3-dihydrobenzofuran-6- yl)methyl)-prop-2-en carbonsäure
AU2002313655A1 (en) 2-(5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl)-succinic acid derivatives as factor viia inhibitors
SI1037888T1 (en) (e)-3-(1-n-butyl- 5-(2-(2-carboxyphenyl)methoxy- 4-chlorophenyl)-1h- pyrazol-4-yl)-2- ((5- methoxy-2,3- dihydrobenzofuran-6-yl)methyl)- prop-2-enoic acid monoargininyl salt
DK1095035T3 (da) Fremgangsmåde til fremstilling af 4-(3-pyridinyl)-1H-imidazol og de anvendte mellemprodukter
DK1273232T3 (da) Fremgangsmåde til fremstilling af herbicidet ethyl-alfa-2-dichlor-5-[4-(difluormethyl)-4,5-dihydro-3-methyl-5-oxo-1H-1,2,4-triazol-1-yl]-4-fluorbenzen-propanoat
IS5166A (is) Kristallað vatnað natríumsalt af (E)-4,6-díklóró-3-(2-oxó-1-fenýlpýrrólidín-3-ýliden metýl)-1h-indól-2-karboxýlsýru
ATE396976T1 (de) Verfahren zur herstellung von 4-(imidazol-1- yl)benzolsulfonamidderivaten
DE59811763D1 (de) Substituierte 4-(3-alkenyl-benzoyl)-pyrazole
AU8505698A (en) Derivatives of 1-((3,3-dimethyl-3-silabutoxy)methyl)-2-(phenylsulfonyl)imid azole
FR2790362B3 (fr) Leurre pour la peche
ID18481A (id) 2-(3,5-difluorofenil)-3-(4-metilsulfonil)fenil)-2-siklopenten-1-on yang berguna sebagai inhibitor cox-2
AU3076395A (en) 7-substituted 1-{4-(1h-1,2,4-triazol-1-yl-methyl)phenyl} substituted quinolone carboxylic acids as antiviral agents
MX9203335A (es) Derivados de 5-[1-(imidazol)metil]2-(3h) furanona 3,3-disubstituidos.
AU2002316573A1 (en) 2-(5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl)-succinic acid derivatives as factor viia inhibitors
IT1313578B1 (it) Metodo per l'essicamento di acido borico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee